sorafenib has been researched along with ginsenoside rg3 in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ginsenoside rg3) | Trials (ginsenoside rg3) | Recent Studies (post-2010) (ginsenoside rg3) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 443 | 9 | 322 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fei, Z; Lu, M; Zhang, G | 1 |
| Hua, H; Ji, H; Lu, T; Ren, Y; Shan, K; Wei, Q; Yang, S; Zheng, X | 1 |
2 other study(ies) available for sorafenib and ginsenoside rg3
| Article | Year |
|---|---|
Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Ginsenosides; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib | 2018 |
Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaprogression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Ginsenosides; Glucose; Glycolysis; Humans; Lactates; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2022 |